Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma

doi:10.35712/aig.120311

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 2

This Article

(6)

(0)

(75)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

Artificial Intelligence in Gastroenterology

ISSN

2644-3236

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

Artif Intell Gastroenterol. Aug 8, 2026; 7(2): 120311
Published online Aug 8, 2026. doi: 10.35712/aig.120311

Table 3 Discrimination gains of artificial intelligence vs conventional models

Clinical context	AI model type	AI performance	Comparator	Comparator performance	Absolute gain	Validation type
Atezo-Bev (advanced HCC)	Radiomic + clinical ML	AUC 0.89 (derivation), 0.75 (external)	BCLC/ALBI	0.61/0.48	+0.14-0.41	Multicenter external
TACE	Radiomic + clinical	AUC approximately 0.79-0.81	Clinical-only	Approximately 0.60	+0.19-0.21	Internal validation

Values represent reported discrimination metrics from individual retrospective studies and are not pooled estimates. Variability reflects differences in study design, patient populations, and validation strategies across cohorts. AI: Artificial intelligence; HCC: Hepatocellular carcinoma; Atezo-Bev: Atezolizumab plus bevacizumab; ML: Machine learning; AUC: Area under the receiver operating characteristic curve; ALBI: Albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization.

Full Size Table

Citation: Meena BL, Behera B, Rudra OS, Sharma D. Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma. Artif Intell Gastroenterol 2026; 7(2): 120311
URL: https://www.wjgnet.com/2644-3236/full/v7/i2/120311.htm
DOI: https://dx.doi.org/10.35712/aig.120311

Meena BL, Behera B, Rudra OS, Sharma D. Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma. Artif Intell Gastroenterol 2026; 7(2): 120311 [DOI: 10.35712/aig.120311]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.